0000000000643196

AUTHOR

Paolo Amari

showing 1 related works from this author

Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.

2014

e20705 Background: To date the anti-emetic prophylaxis based on the combination of 5HT3-antagonists and corticosteroids is mandatory for high and moderate emetogenic cytotoxic agents. This approach...

Anti vegfCancer Researchbusiness.industrymedicine.drug_classmedicine.diseaseMonoclonal antibodyBreast cancerOncologyCancer researchMedicineAntiemeticAnti her2CytotoxicitybusinessJournal of Clinical Oncology
researchProduct